Objectives: To examine trends in the licit consumption of the psychostimulants dexamphetamine and methylphenidate in Australia and nine other countries from 1994 to 2000 and in each State and Territory of Australia from 1984 to 2000.
Design: Annual rates of consumption of psychostimulants were compared using Poisson regression models. All drug consumption was standardised to defined daily doses per 1000 population per day.
Main outcome measures: Rates of consumption of each psychostimulant in each country and in each Australian State and Territory.
Results: For the 10 countries from 1994 to 2000, total psychostimulant consumption increased by an average 12% per year, with the highest increase from 1998 to 2000. Australia and New Zealand ranked third in total psychostimulant use after the United States and Canada. Australia consumed significantly more than the United Kingdom, Sweden, Spain, the Netherlands, France or Denmark. In Australia, from 1984 to 2000, the rate of consumption of licit psychostimulants increased by 26% per year, with an 8.46-fold increase from 1994 to 2000. Western Australia ranked first, with nearly twice the consumption rate of total psychostimulants as New South Wales, which ranked second. Methylphenidate is the main psychostimulant consumed in the US and Canada, and dexamphetamine in Australia.
Conclusions: The consumption of psychostimulants in Australia is high internationally and varies significantly between States and Territories. The results imply varied jurisdictional prescribing determinants and supply processes throughout Australia, which may require new national prescribing standards and access to online patient data for prescribers and dispensers.
- 1. Elia J, Ambrosini PJ, Rapoport JL. Drug therapy: treatment of attention-deficit-hyperactivity disorder. N Engl J Med 1999; 340: 780-788.
- 2. Stimulant drugs for hyperactivity in childhood. Drug Ther Bull 2001; 39: 42-44.
- 3. National Health and Medical Research Council. Attention deficit hyperactivity disorder. Canberra: Commonwealth of Australia, 1997. Available at <http://www.health.gov.au/nhmrc/publications/adhd/contents.htm>
- 4. Marshall E. Planned Ritalin trial for tots heads into uncharted waters. Science 2000; 290: 1280-1282.
- 5. National Institute for Clinical Excellence. Guidance on the use of methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood. London: NICE, 2000. Available at: <http://www.nice.org.uk/pdf/Methylph-guidance13.pdf>. Accessed 8 August 2002.
- 6. Poulin C. Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use. CMAJ 2001; 165: 1039-1044.
- 7. Graetz BW, Sawyer MG, Hazell P, et al. Validity of DSM-IV ADHD subtypes in a nationally representative sample of Australian children and adolescents. J Am Acad Child Adolesc Psychiatry 2001; 40: 141-147.
- 8. Safer DJ, Malever M. Stimulant treatment in Maryland public schools. Pediatrics 2000; 106: 533-539.
- 9. Schirm E, Tobi H, Zito JM, de Jong-van den Berg LTW. Psychotropic medication in children: a study from the Netherlands. Pediatrics 2001; 108: e25. <http://www.pediatrics.org/cgi/content/full/108/2/e25>. Accessed 8 August 2002.
- 10. Sawyer MG, Rey JM, Graetz BW, et al. Use of medication by young people with attention deficit/hyperactivity disorder. Med J Aust 2002; 177: 21-25. <MJA full text>
- 11. Valentine J, Zubrick S, Sly P. National trends in the use of stimulant medication for attention deficit hyperactivity disorder. J Paediatr Child Health 1996; 32: 223-227.
- 12. Prosser B, Reid R. Psychostimulant use for children with ADHD in Australia. J Emotional Behav Disord 1999; 7: 110-117.
- 13. Mackey P, Kopras A. Medication for attention deficit hyperactivity disorder (ADHD): an analysis by Federal electorate. Current Issues Brief 11 2000-01. Canberra: Parliament of Australia Parliamentary Library, 2001. Available at <http://www.aph.gov.au/library/pubs/cib/2000-01/01cib11.htm>.
- 14. Salmelainen P. Trends in the prescribing of stimulant medication for the treatment of attention deficit hyperactivity disorder in children and adolescents in NSW. Sydney: NSW Department of Health, 2002. Available at <http://www.health.nsw.gov.au/public-health/phbsup/ADHD2002sup.pdf>.
- 15. International Narcotics Control Board. Narcotic drugs: estimated world requirements for 2001. Statistics for 1999. New York: United Nations, 2001.
- 16. Berbatis CG, Sunderland VB, Bulsara M, Lintzeris N. Trends in licit opioid use in Australia, 1984–1998: comparative analysis of international and jurisdictional data. Med J Aust 2000; 173: 524-527.
- 17. WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway. Anatomical Therapeutic Chemical classification index with defined daily doses (DDDs). January 2001. <http://www.whocc.no/atcddd/>. Accessed 16 September 2002.
- 18. Gardner W, Mulvey E, Shaw E. Regression analyses of counts and rates: Poisson, overdispersed Poisson and negative binomial models. Psychol Bull 1995; 118: 392-404.
- 19. SAS/STAT software [computer program]. Release 8.2. Cary, NC: SAS Institute, 2002.
- 20. US Census Bureau. International data base. Online demographic aggregation. <http://www.census.gov/ipc/www/idbnew.html>. Accessed 8 August 2002
- 21. Topp L, Kaye S, Bruno R, et al. Australian drug trends 2001. Findings of the Illicit Drug Reporting System (IDRS). NDARC Monograph No. 48. Sydney: NDARC, 2002; 36.
- 22. Vikingur MJ. The non-prescribed use of dexamphetamine sulphate and methylphenidate hydrochloride among students in Perth high schools. Master of Special Education. Perth: University of Western Australia Graduate School of Education, 2001.
- 23. Harvey B. Child drug deals: 500,000 pills sold a year. Year 3s caught out. The West Australian 2001: 11 August: 1, 10.
- 24. Zafer H, McAnuff K. HIC concerns on supply of dexamphetamine. Pharmaceutical Guild of Australia, WA Branch, Perth. Pharmacy Guild Bulletin 2001; Issue 873 (18 May): 3.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.